DOCSLIB.ORG

Small Animal Formulary 6Th Edition

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Small Animal Formulary 6Th Edition BSAVA Small Animal Formulary Ian Ramsey 6th edition Small Animal Formulary 6th edition Editor-in-Chief: Ian Ramsey BVSc PhD DSAM DipECVIM-CA FHEA MRCVS Small Animal Hospital, University of Glasgow, Bearsden Road, Bearsden, Glasgow G61 1QH Published by: British Small Animal Veterinary Association Woodrow House, 1 Telford Way, Waterwells Business Park, Quedgeley, Gloucester GL2 2AB A Company Limited by Guarantee in England. Registered Company No. 2837793. Registered as a Charity. Copyright © 2008 BSAVA First edition 1994 Second edition 1997 Third edition 1999 Reprinted with corrections 2000 Fourth edition 2002 Reprinted with corrections 2003 Fifth edition 2005 Reprinted with corrections 2007 All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in form or by any means, electronic, mechanical, photocopying, recording or otherwise without prior written permission of the copyright holder. A catalogue record for this book is available from the British Library. ISBN 978 1 905319 11 4 The publishers and contributors cannot take responsibility for information provided on dosages and methods of application of drugs mentioned in this publication. Details of this kind must be verified by individual users from the appropriate literature. Printed by: HSW Print, Rhondda, Wales. ii BSAVA Small Animal Formulary 6th edition Other titles from BSAVA: Manual of Canine & Feline Abdominal Surgery Manual of Canine & Feline Anaesthesia and Analgesia Manual of Canine & Feline Behavioural Medicine Manual of Canine & Feline Clinical Pathology Manual of Canine & Feline Dentistry Manual of Canine & Feline Emergency and Critical Care Manual of Canine & Feline Endocrinology Manual of Canine & Feline Endoscopy and Endosurgery Manual of Canine & Feline Gastroenterology Manual of Canine & Feline Haematology and Transfusion Medicine Manual of Canine & Feline Head, Neck and Thoracic Surgery Manual of Canine & Feline Infectious Diseases Manual of Canine & Feline Musculoskeletal Disorders Manual of Canine & Feline Musculoskeletal Imaging Manual of Canine & Feline Nephrology and Urology Manual of Canine & Feline Neurology Manual of Canine & Feline Oncology Manual of Canine & Feline Thoracic Imaging Manual of Canine & Feline Wound Management and Reconstruction Manual of Exotic Pets Manual of Farm Pets Manual of Ornamental Fish Manual of Practical Animal Care Manual of Practical Veterinary Nursing Manual of Psittacine Birds Manual of Rabbit Medicine and Surgery Manual of Raptors, Pigeons and Passerine Birds Manual of Reptiles Manual of Small Animal Cardiorespiratory Medicine and Surgery Manual of Small Animal Dermatology Manual of Small Animal Diagnostic Imaging Manual of Small Animal Fracture Repair and Management Manual of Small Animal Ophthalmology Manual of Small Animal Reproduction and Neonatology Manual of Wildlife Casualties Textbook of Veterinary Nursing For information on these and all BSAVA publications please visit our website: www.bsava.com BSAVA Small Animal Formulary 6th edition iii Contents Editorial Panel iv Preface to the sixth edition vi Foreword viii Introduction How to use the Formulary ix Distribution categories x The cascade xii ‘Off-label’ use of medicines xii Drug storage and dispensing xiv Health and safety in dispensing xv Drug listings and monographs 1 (listed A–Z by generic name) Appendix Abbreviations 358 Writing a prescription 359 Body weight to body surface area conversion tables 360 Percentage solutions 361 Dosing small and exotic animals 361 Antibacterial selection 362 Radiographic contrast agents Barium contrast media 364 Iodinated contrast media 365 MRI contrast media 367 Composition of intravenous fluids 370 Pancreatic enzyme supplements 371 Polypharmaceuticals 372 Sedative protocols Sedative combinations for dogs 372 Sedative combinations for cats 374 Sedative combinations for exotic pets 376 Chemotherapy protocols for lymphoma 378 Drugs usage in renal and hepatic insufficiency 379 Further reading 382 Suspected Adverse Reaction Form 383 Index sorted by therapeutic class 385 Index (alphabetical by generic and trade names) 392 Errata 405 iv BSAVA Small Animal Formulary 6th edition Editorial Panel Sally Anne Argyle MVB CertSAC PhD MRCVS Royal (Dick) School of Veterinary Studies, University of Edinburgh, Hospital for Small Animals, Easter Bush Veterinary Centre, Roslin, Midlothian EH25 9RG John Chitty BVetMed CertZooMed MRCVS Strathmore Veterinary Clinic, London Road, Andover, Hants SP10 2PH Jane Dobson MA DVetMed DipECVIM-CA(Oncology) MRCVS Department of Veterinary Medicine, University of Cambridge, Madingley Road, Cambridge CB3 0ES Clive M. Elwood MA VetMB MSc PhD CertSAC DipACVIM DipECVIM-CA MRCVS Davies Veterinary Specialists, Manor Farm Business Park, Higham Gobion, Hitchin, Herts SG5 3HR Heidi Featherstone BVetMed DVOphthal DipECVO MRCVS Willows Referral Service, 78 Tanworth Lane, Shirley, Solihull, West Midlands B90 4DF Simon Girling BVMS (Hons) DZooMed CBiol MIBiol MRCVS Muirfield, Glenfarg, Perthshire PH2 9QD Edward J. Hall MA VetMB PhD DipECVIM-CA MRCVS Department of Clinical Veterinary Science, University of Bristol, Langford House, Langford, Bristol BS40 5DU Hilary A. Jackson BVM&S DVD DipACVD MRCVS Dermatology Referral Practice, 528 Paisley Road West, Glasgow G64 4JG Mark W. Jackson BSc DVM PhD DipACVIM MRCVS Small Animal Hospital, University of Glasgow, Bearsden Road, Bearsden, Glasgow G61 1QH Mike Stafford Johnson MVB CertSAM MACVS DVC MRCVS 43 Waverley Road, Kenilworth, Warwickshire CV8 1JL Fraser McConnell BVM&S DVR DipECVDI CertSAM MRCVS Small Animal Teaching Hospital, University of Liverpool, Leahurst, Chester High Road, Neston, Wirral CH64 7TE Anna Meredith MA VetMB CertLAS DZooMed MRCVS Royal (Dick) School of Veterinary Studies, University of Edinburgh, Hospital for Small Animals, Easter Bush Veterinary Centre, Roslin, Midlothian EH25 9RG BSAVA Small Animal Formulary 6th edition v Daniel S. Mills BVSc PhD CBiol MIBiol ILTM CCAB DipECVBM-CA MRCVS Biological Sciences Department, University of Lincoln, Riseholme Park, Lincoln LN2 2LG Jo Murrell BVSc (Hons) PhD DipECVAA MRCVS Department of Clinical Veterinary Science, University of Bristol, Langford House, Langford, Bristol BS40 5DU Jacques Penderis BVSc MVM PhD CertVR DipECVN MRCVS Small Animal Hospital, University of Glasgow, Bearsden Road, Bearsden, Glasgow G61 1QH Ian Ramsey BVSc PhD DSAM DipECVIM-CA FHEA MRCVS Small Animal Hospital, University of Glasgow, Bearsden Road, Bearsden, Glasgow G61 1QH Richard Saunders BSc BVSc CertZooMed CIBiol MIBiol MRCVS Veterinary Department, Bristol Zoo Gardens, Bristol BS8 3HA vi BSAVA Small Animal Formulary 6th edition Preface to the sixth edition The BSAVA Small Animal Formulary enters its sixth edition with a new Editor-in-Chief and a new look. In the three years since the last edition there has been a considerable change in the classification of medicines. The details of this are presented in the Introduction and the new classification is used throughout. However, many of the drugs listed in the Formulary still remain unauthorized for the species we treat. Authorized products should always be considered first for every patient. If unauthorized drugs are to be used ahead of a authorized product there must be a clear and definable clinical advantage to their use. Frequently one unauthorized medication is preferred to another. Another new development is the inclusion in the monographs of information on specific handling requirements or human safety issues. Comments on the general handling of all drugs, including best dispensing practice, have been included in the Introduction. I urge all veterinary surgeons to read and follow this advice. The profession’s continuing legal authority to dispense medications depends on a demonstrably responsible attitude to pharmacy practice. The BSAVA Small Animal Formulary should never be the only source of information that is consulted by veterinary surgeons and nurses who are confronted with a medication that they have not used before. The format of the Formulary does not allow a detailed discussion of the use of a particular drug. Relevant textbooks, such as the excellent series of Manuals published by the BSAVA, should be consulted as well. The Formulary is designed as an aide mémoire for drugs with which readers are already partly familiar. A list of further reading is provided in this Formulary. Many of the drug uses, doses and adverse reactions that are recorded in this Formulary are taken from textbooks, which in turn have taken their information from a detailed analysis of the peer- reviewed literature. However, some information is less clear or less authoritative, particularly when considering the use of drugs in exotic species. Some information is derived from unreferenced sources, congress abstracts and even anecdotal personal communications. Ideally all drug uses, doses and adverse reactions would be obtained from well referenced sources with independent corroboration. This nirvana will not be achieved for many years, if ever. Therefore, the authors of the Formulary are now providing references for many of the drugs. This information, which will gradually be provided on the web-based version of the Formulary but not in the paper copy, will allow users to assess the level of evidence for a particular recommendation and act accordingly. BSAVA Small Animal Formulary 6th edition vii I am grateful for all the comments that have been made in the process of preparing this sixth edition and any comments on this new edition are
Load more

Recommended publications
  • Sous Forme De Sel De Calcium
    Nom molécule Abamectine Absinthe (teinture de) Acamprosate (sous forme de sel de calcium) Acarbose Acébutolol (sous forme de chlorhydrate) Acéclofénac Acéfylline heptaminol Acémétacine Acépromazine Acépromazine (sous forme de maléate) Acétate de calcium Acétate de magnésium (sous forme de tétrahydrate) Acétate de potassium Acétate de sodium Acétate de sodium (sous forme de trihydrate) Acétazolamide Acétylcholine (sous forme de chlorure) Acétylcystéine Acétylméthionine Acétylméthionine (sous forme de sel de magnésium) Achillée millefeuille Aciclovir Acide acétylsalicylique Acide acétylsalicylique (sous forme de carbasalate de calcium) Acide acétylsalicylique (sous forme de lysinate) Acide acétylsalicylique (sous forme de sel de sodium) Acide adipique Acide alendronique (sous forme de sel de sodium) Acide alginique Acide alginique (sous forme de sel de calcium) Acide aminocaproïque Acide ascorbique Acide ascorbique (sous forme de sel de calcium) Acide ascorbique (sous forme de sel de sodium) Acide aspartique Acide aspartique (sous forme de sel de calcium) Acide aspartique (sous forme de sel de magnésium) Acide aspartique (sous forme de sel de magnésium et de potassium) Acide aspartique (sous forme de sel de magnésium et de potassium dihydraté) Acide aspartique (sous forme de sel de magnésium tétrahydraté) Acide aspartique (sous forme de sel de potassium) Acide aspartique (sous forme de sel de potassium hémihydraté) Acide aspartique (sous forme de zinc) Acide benzoïque Acide benzoïque (sous forme de benzyle) Acide benzoïque (sous forme de
    [Show full text]
  • Lääkealan Turvallisuus- Ja Kehittämiskeskuksen Päätös
    Lääkealan turvallisuus- ja kehittämiskeskuksen päätös N:o xxxx lääkeluettelosta Annettu Helsingissä xx päivänä maaliskuuta 2016 ————— Lääkealan turvallisuus- ja kehittämiskeskus on 10 päivänä huhtikuuta 1987 annetun lääke- lain (395/1987) 83 §:n nojalla päättänyt vahvistaa seuraavan lääkeluettelon: 1 § Lääkeaineet ovat valmisteessa suolamuodossa Luettelon tarkoitus teknisen käsiteltävyyden vuoksi. Lääkeaine ja sen suolamuoto ovat biologisesti samanarvoisia. Tämä päätös sisältää luettelon Suomessa lääk- Liitteen 1 A aineet ovat lääkeaineanalogeja ja keellisessä käytössä olevista aineista ja rohdoksis- prohormoneja. Kaikki liitteen 1 A aineet rinnaste- ta. Lääkeluettelo laaditaan ottaen huomioon lää- taan aina vaikutuksen perusteella ainoastaan lää- kelain 3 ja 5 §:n säännökset. kemääräyksellä toimitettaviin lääkkeisiin. Lääkkeellä tarkoitetaan valmistetta tai ainetta, jonka tarkoituksena on sisäisesti tai ulkoisesti 2 § käytettynä parantaa, lievittää tai ehkäistä sairautta Lääkkeitä ovat tai sen oireita ihmisessä tai eläimessä. Lääkkeeksi 1) tämän päätöksen liitteessä 1 luetellut aineet, katsotaan myös sisäisesti tai ulkoisesti käytettävä niiden suolat ja esterit; aine tai aineiden yhdistelmä, jota voidaan käyttää 2) rikoslain 44 luvun 16 §:n 1 momentissa tar- ihmisen tai eläimen elintoimintojen palauttami- koitetuista dopingaineista annetussa valtioneuvos- seksi, korjaamiseksi tai muuttamiseksi farmako- ton asetuksessa kulloinkin luetellut dopingaineet; logisen, immunologisen tai metabolisen vaikutuk- ja sen avulla taikka terveydentilan
    [Show full text]
  • WO 2014/125397 Al 21 August 2014 (21.08.2014) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization II International Bureau (10) International Publication Number (43) International Publication Date WO 2014/125397 Al 21 August 2014 (21.08.2014) P O P C T (51) International Patent Classification: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, C07D 513/04 (2006.01) A61P 3/10 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, A61K 31/542 (2006.01) A61P 25/28 (2006.01) HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, (21) International Application Number: MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, PCT/IB2014/058777 OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (22) International Filing Date: SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, 4 February 2014 (04.02.2014) TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of regional protection available): ARIPO (BW, GH, (30) Priority Data: GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, 61/765,283 15 February 2013 (15.02.2013) US UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, (71) Applicant: PFIZER INC. [US/US]; 235 East 42nd Street, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, New York, New York 10017 (US).
    [Show full text]
  • Evaluation of the Efficacy of IQV04 for Weight Loss in Overweight and Obese Dogs
    Evaluation of the efficacy of IQV04 for weight loss in overweight and obese dogs. Annika Bieze 3514870 Supervisor: Dr. R.J. Corbee Abstract Introduction: Overweight and obesity are worldwide problems. Because of the higher risk of associated diseases, it is better to prevent and treat overweight and obesity. Beside weight loss programs, there are different medications and supplements available. After promising results from human health studies on the efficacy of Litramine, a similar product, named IQV04, is developed for dogs to support weight loss. The objective of this study was to evaluate the efficacy of IQV04 for weight loss in overweight and obese dogs. Materials and methods: Nineteen colony dogs were randomly divided in three groups, in this placebo controlled and double-blinded study. All dogs received once a day a standardised maintenance meal for their resting energy requirement (RER) with one of the three pills (IQV04 concentration A, IQV04 concentration B and placebo). Body weight and pelvic circumference were measured weekly. By start and end of the study, physical examination, body condition score, complete blood count, serum biochemical analysis and fecal examination was done. Results: Results suggested that there was a difference in body weight reduction between the three groups. The rate of weight loss in the placebo, IQV04 concentration A and IQV04 concentration B group were 2.45 ± 0.51, 2.85 ± 1.84 and 3.03 ± 1.26% body weight reduction per week, respectively. However, this difference did not reach significance. Also there was no significant difference found in pelvic circumference reduction per week. Conclusion: Further studies with larger patient pool are required to achieve more statistic power.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • A Abacavir Abacavirum Abakaviiri Abagovomab Abagovomabum
    A abacavir abacavirum abakaviiri abagovomab abagovomabum abagovomabi abamectin abamectinum abamektiini abametapir abametapirum abametapiiri abanoquil abanoquilum abanokiili abaperidone abaperidonum abaperidoni abarelix abarelixum abareliksi abatacept abataceptum abatasepti abciximab abciximabum absiksimabi abecarnil abecarnilum abekarniili abediterol abediterolum abediteroli abetimus abetimusum abetimuusi abexinostat abexinostatum abeksinostaatti abicipar pegol abiciparum pegolum abisipaaripegoli abiraterone abirateronum abirateroni abitesartan abitesartanum abitesartaani ablukast ablukastum ablukasti abrilumab abrilumabum abrilumabi abrineurin abrineurinum abrineuriini abunidazol abunidazolum abunidatsoli acadesine acadesinum akadesiini acamprosate acamprosatum akamprosaatti acarbose acarbosum akarboosi acebrochol acebrocholum asebrokoli aceburic acid acidum aceburicum asebuurihappo acebutolol acebutololum asebutololi acecainide acecainidum asekainidi acecarbromal acecarbromalum asekarbromaali aceclidine aceclidinum aseklidiini aceclofenac aceclofenacum aseklofenaakki acedapsone acedapsonum asedapsoni acediasulfone sodium acediasulfonum natricum asediasulfoninatrium acefluranol acefluranolum asefluranoli acefurtiamine acefurtiaminum asefurtiamiini acefylline clofibrol acefyllinum clofibrolum asefylliiniklofibroli acefylline piperazine acefyllinum piperazinum asefylliinipiperatsiini aceglatone aceglatonum aseglatoni aceglutamide aceglutamidum aseglutamidi acemannan acemannanum asemannaani acemetacin acemetacinum asemetasiini aceneuramic
    [Show full text]
  • WO 2013/150416 Al 10 October 2013 (10.10.2013) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization I International Bureau (10) International Publication Number (43) International Publication Date WO 2013/150416 Al 10 October 2013 (10.10.2013) P O P C T (51) International Patent Classification: sachusetts 02460 (US). FUTATSUGI, Kentaro; 97 West C07D 471/04 (2006.01) A61K 31/519 (2006.01) Main Street, Unit 29, Niantic, Connecticut 06357 (US). C07D 473/32 (2006.01) A61K 31/52 (2006.01) HEPWORTH, David; 282 Sudbury Road, Concord, M as C07D 487/04 (2006.01) A61P 3/10 (2006.01) sachusetts 01742 (US). KUNG, Daniel W.; 289 Laurel- C07D 519/00 (2006.01) wood Drive, Salem, Connecticut 06420 (US). ORR, Suvi; 16 Seabreeze Road, Old Saybrook, Connecticut 06475 (21) International Application Number: (US). WANG, Jian; 164 White Street, Belmont, Mas PCT/IB20 13/052404 sachusetts 02478 (US). (22) International Filing Date: (74) Agents: KLEIMAN, Gabriel L. et al; Pfizer Inc., 235 26 March 2013 (26.03.2013) East 42nd Street, New York, NY 1001 7 (US). (25) Filing Language: English (81) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (30) Priority Data: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, 61/621,144 6 April 2012 (06.04.2012) US DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (71) Applicant: PFIZER INC. [US/US]; 235 East 42nd Street, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, New York, New York 10017 (US).
    [Show full text]
  • Small Animal Obesity: Effective Control, Management and Care
    Vet Times The website for the veterinary profession https://www.vettimes.co.uk SMALL ANIMAL OBESITY: EFFECTIVE CONTROL, MANAGEMENT AND CARE Author : Catherine F Le Bars Categories : Vets Date : February 23, 2009 Catherine F Le Bars explains how the battle of the bulge and the medical implications specific to certain species need a careful approach to both owner and pet OBESITY is one of the most common nutrition-related conditions in companion animals in the industrialised world, and has a proven association with the development of several disease conditions and reduced longevity. Since weight gain occurs when daily energy intake exceeds energy expenditure, the prevention of obesity requires strict attention to the animal’s nutrition throughout its life. Obesity treatment may be complicated by many factors, and successful management of the condition relies on rigorous owner compliance. Estimates from around the world put the incidence of obesity in dogs and cats at up to 40 per cent, and a number of risk factors have been implicated in its development. These include breed, age, gender, neutering, medication (anti-convulsants, glucocorticoids and contraceptives), lifestyle and exercise, co-existing disease (diabetes mellitus, hypothyroidism, hyperadrenocorticism) and diet. The regulation of food intake is dependent on a complex balance of long-term and shortterm signals to the brain, which are aimed at controlling the fat mass of the animal. When this balance is disrupted, the animal consumes energy above its requirements and gains weight. There are three recognised stages of weight gain: 1 / 10 • A “static ” pre-obesity stage, whereby energy intake is increased but bodyweight remains the same.
    [Show full text]
  • The Comparison of the Effect of Dietary Changes Or Dirlotapide
    THE COMPARISON OF THE EFFECT OF DIETARY CHANGES OR DIRLOTAPIDE TREATMENT ON CANINE OBESITY IN A SMALL ANIMAL VETERINARY PRACTICE A Report of a Senior Study by Anna Elizabeth McRee Major: Biology Maryville College Fall, 2009 Date Approved _____________, by ________________________ Faculty Supervisor Date Approved _____________, by ________________________ Editor ii ABSTRACT One of the greatest clinical challenges in contemporary veterinary medicine is canine obesity, which in the U.S. is increasing similar to trends observed in humans. Obesity impedes the overall wellness of canine patients; it is associated with shorter lifespan in domesticated dogs. The purposes of this study were to evaluate the incidence of obesity in one particular East Tennessee small animal veterinary practice and to examine the efficacy of two readily available treatment tools for this disease: pharmaceutical therapy with dirlotapide or dietary intervention through either caloric restriction or a high fiber diet. The incidence of obesity was examined by recording the body condition score (BCS) on a 1-9 scale for every dog that entered My Pets Animal Hospital for 2 consecutive months during the summer of 2009. Data for 594 dogs was collected in this manner and 4 treatment groups were also evaluated to examine the efficacy of treatment protocols. This study presents two major findings: (1) that 67 % of dogs at this particular veterinary clinic were overweight/obese (based on a BCS score of 6 or greater) and (2) that both dietary changes and pharmaceutical treatment were equally effective at promoting weight reduction in obese canines, as there was no significant difference in the percent weight loss per 30 days (p = 0.969).
    [Show full text]
  • Phytochemicals for Controlling Obesity-Related Cancers
    Crimson Publishers Review Article Wings to the Research Phytochemicals for Controlling Obesity-Related Cancers Madhumita Roy1*and Amitava Datta2 1Department of Environmental Carcinogenesis and Toxicology, Chittaranjan National Cancer Institute, 37, S. P. Mukherjee Road, Kolkata-700026, India 2Department of Computer Science and Software Engineering, University of Western Australia. 35 Stirling Highway, Perth, WA 6009, Australia ISSN: 2637-773X Abstract Obesity related diseases are on the rise worldwide and obesity is an economic burden on the public health system in most developed and developing countries. The control of obesity is a major challenge that is hard to solve using medication and surgical procedures as those often have serious side effects. Our focus in this article is to highlight the extensive research literature on use of plant-derived chemicals or phytochemicals for control of obesity and obesity related diseases with a particular focus on several types of cancer. We discuss the genes, proteins and pathways involved in obesity and its control, and discuss these genes and pathways. how current research has revealed the beneficial effects of plant-derived chemicals or phytochemicals on Keywords: Obesity; Phytochemicals; Cancer; Adiposity; BMI; Signalling pathways; Genes Introduction *Corresponding author: Madhumita Roy, Department of Environmental Obesity is the state of being overweight, a condition caused due to excessive rate of Carcinogenesis and Toxicology, accumulation and storage of fat in the body. Obesity not only affects appearance, but leads Chittaranjan National Cancer Institute, 37, to a number of health issues. The disparity in calorie consumption and calorie burning leads S. P. Mukherjee Road, Kolkata-700026, to energy imbalance, which is a lead cause of obesity.
    [Show full text]
  • Chemical Structure-Related Drug-Like Criteria of Global Approved Drugs
    Molecules 2016, 21, 75; doi:10.3390/molecules21010075 S1 of S110 Supplementary Materials: Chemical Structure-Related Drug-Like Criteria of Global Approved Drugs Fei Mao 1, Wei Ni 1, Xiang Xu 1, Hui Wang 1, Jing Wang 1, Min Ji 1 and Jian Li * Table S1. Common names, indications, CAS Registry Numbers and molecular formulas of 6891 approved drugs. Common Name Indication CAS Number Oral Molecular Formula Abacavir Antiviral 136470-78-5 Y C14H18N6O Abafungin Antifungal 129639-79-8 C21H22N4OS Abamectin Component B1a Anthelminithic 65195-55-3 C48H72O14 Abamectin Component B1b Anthelminithic 65195-56-4 C47H70O14 Abanoquil Adrenergic 90402-40-7 C22H25N3O4 Abaperidone Antipsychotic 183849-43-6 C25H25FN2O5 Abecarnil Anxiolytic 111841-85-1 Y C24H24N2O4 Abiraterone Antineoplastic 154229-19-3 Y C24H31NO Abitesartan Antihypertensive 137882-98-5 C26H31N5O3 Ablukast Bronchodilator 96566-25-5 C28H34O8 Abunidazole Antifungal 91017-58-2 C15H19N3O4 Acadesine Cardiotonic 2627-69-2 Y C9H14N4O5 Acamprosate Alcohol Deterrant 77337-76-9 Y C5H11NO4S Acaprazine Nootropic 55485-20-6 Y C15H21Cl2N3O Acarbose Antidiabetic 56180-94-0 Y C25H43NO18 Acebrochol Steroid 514-50-1 C29H48Br2O2 Acebutolol Antihypertensive 37517-30-9 Y C18H28N2O4 Acecainide Antiarrhythmic 32795-44-1 Y C15H23N3O2 Acecarbromal Sedative 77-66-7 Y C9H15BrN2O3 Aceclidine Cholinergic 827-61-2 C9H15NO2 Aceclofenac Antiinflammatory 89796-99-6 Y C16H13Cl2NO4 Acedapsone Antibiotic 77-46-3 C16H16N2O4S Acediasulfone Sodium Antibiotic 80-03-5 C14H14N2O4S Acedoben Nootropic 556-08-1 C9H9NO3 Acefluranol Steroid
    [Show full text]
  • List Item Yarvitan : EPAR
    SCIENTIFIC DISCUSSION 1 SUMMARY OF THE DOSSIER Yarvitan, a 5 mg/ml, oral solution contains mitratapide as active substance. Mitratapide is a potent inhibitor of the microsomal triglyceride transfer protein (MTP). The benefits of Yarvitan are its ability to reduce bodyweight in adult dogs when given in accordance with the approved treatment schedule of 2 periods of 21 days with 14 days without treatment in between. The majority of overweight dogs are overweight from excess body fat. Several predisposing factors relate to the development of obesity in companion animals, including: advancing age, breed, neutering, excessive or inappropriate feeding and infrequent exercise or inactivity. The treatment with Yarvitan is given orally with food once daily. The most common side effects are vomiting, diarrhoea or softened stools. 2. QUALITY ASSESSMENT Composition authorised Yarvitan oral solution contains 5 mg/ml mitratapide as active substance. Conventional pharmaceutical excipients (flavouring agent, anti-oxidant and solvent) are used and full details are included in the SPC. Container Yarvitan is presented in amber glass bottles with polypropylene child resistant caps with a low density polyethylene (LDPE) liner fitted with an insert for an LDPE/polystyrene dosing pipette. The dosing pipette is supplied separately to the bottle and two separate dosinglonger pipettes sizes are available. A 4 ml pipette will be supplied with the 55 and 120 ml bottles and a 6 ml pipette with the 210 ml bottle. Three container volumes are proposed: 55 ml (in 60 ml nominal bottle) - 120 ml (in 125 ml nominal bottle) - 210 ml (in 230 ml nominal bottle). All packaging components are suitable for pharmaceutical use.
    [Show full text]